Fosun Pharma acquires 77.8% stake in central nervous system and hemostatic drugmaker Hunan Dongting for a consideration of around $93 million

Fosun Pharma has been focused on CNS drugs in the therapeutic areas and drug development and production with high barriers to entry. The acquisition of Dongting, will will further strengthen its product lines and competitive positioning in the CNS drugs sector in China.


Dongting is a leader in domestic psychotropic drugs, and is one of the main production bases of China’s psychotropic drugs and hemostatic drugs; its leading product is fumarate quetiapine tranexamic acid.